Vyvanse FDA Approval History
FDA Approved: Yes (First approved February 23, 2007)
Brand name: Vyvanse
Generic name: lisdexamfetamine dimesylate
Dosage form: Capsules
Company: Shire plc
Treatment for: ADHD
Vyvanse (lisdexamfetamine dimesylate) is an amphetamine derivative prodrug administered once-daily for the treatment of attention deficit hyperactivity disorder (ADHD) and binge-eating disorder.
Development timeline for Vyvanse
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.